Podcasts about Precision medicine

Most doctors treat the average patient. But you are not average, and this episode gives you the precision medicine blueprint to treat yourself like the individual you are, using multi-omic testing, biohacking technology, and longevity science to optimize every layer of your biology. -Watch this episode on YouTube for the full video experience: https://www.youtube.com/@DaveAspreyBPR Host Dave Asprey sits down with Dr. Anil Bajnath, a Board-Certified Family Physician, author of The Longevity Equation, and President and Founder of the American Board of Precision Medicine. He serves as Adjunct Professor at the George Washington University School of Medicine and CEO of the Institute for Human Optimization. Dr. Bajnath is certified through the Institute for Functional Medicine, board certified in anti-aging and regenerative medicine, and is one of the few clinicians actively applying genomics, transcriptomics, proteomics, and epigenetics together in a real clinical practice. Together, Dave and Dr. Bajnath break down why population-based medicine fails individuals, how functional medicine and precision science combine to unlock real human performance, and why your mitochondria sit at the foundation of every longevity strategy worth pursuing. They dig into how AI can help you decode your own inflammasome biology, why biohackers are using “sex drugs” to extend longevity, why vagal nerve stimulation directly suppresses the NLRP3 inflammasome, and which biomarkers like MMP9 and homocysteine mainstream medicine keeps ignoring. They also cover peptides, supplements, the dark side of metformin, microdosing for anti-aging, and why biohacking works best when it's personalized and precise. This is essential listening for anyone serious about longevity, smarter not harder health strategies, metabolism, sleep optimization, brain optimization, functional medicine, and taking full control of their biology. You'll Learn: Why precision medicine outperforms population-based health strategies for human performance How to layer genomics, transcriptomics, and proteomics into one complete biological picture Which longevity biomarkers your doctor is likely ignoring, including MMP9 and homocysteine How vagal nerve stimulation suppresses the NLRP3 inflammasome and drives anti-aging benefits The real story on metformin, peptides, and which supplements actually move the needle How AI can help you understand your own biology and act on it faster Why biohacking precision beats random stacking every time Thank you to our sponsors! • Igniton | Head over to Igniton.com and use code DAVE for an exclusive 15% off your first order. • BEYOND Biohacking Conference 2026 | Register with code DAVE300 for $300 off https://beyondconference.com • Caldera + Lab | Go to https://calderalab.com/DAVE and use code DAVE at checkout for 20% off your first order. • Screenfit | Get your at-home eye training program for 40% off using code DAVE at https://www.screenfit.com/dave. Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade brings you the knowledge to take control of your biology, extend your longevity, and optimize every system in your body and mind. Each episode delivers cutting-edge insights in health, performance, neuroscience, supplements, nutrition, biohacking, emotional intelligence, and conscious living. New episodes are released every Tuesday, Thursday, Friday, and Sunday (BONUS). Dave asks the questions no one else will and gives you real tools to become stronger, smarter, and more resilient. Keywords: precision medicine, biohacking, Dave Asprey Cialis, Anil Bajnath, American Board of Precision Medicine, multi-omics, genomics, transcriptomics, proteomics, epigenetics, NLRP3 inflammasome, vagal nerve stimulation, MMP9, homocysteine, mitochondria, longevity, anti-aging, peptides, BPC-157, metformin, rapamycin, functional medicine, human performance, supplements, EGCG, exposome, nitric oxide, vascular health, metabolism, brain optimization, AI health, biohacking technology, Dave Asprey Sex Drugs Resources: • Learn More About Anil's Work And the Institute For Human Optimization At: https://ifho.org/ • Get My 2026 Clean Nicotine Roadmap | Enroll for free at https://daveasprey.com/2026-clean-nicotine-roadmap/ • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/ • Upgrade Labs: https://upgradelabs.com Timestamps: 00:00 – Trailer 00:53 – Intro to Precision Medicine 01:58 – Dr. Bajnath's Holistic Health Journey 05:03 – Pharmaceuticals vs. Supplements 07:58 – Peptides and Longevity Molecules 10:34 – Sexual Health and Vitality 13:56 – Vascular Health and Blood Flow 15:14 – Multi-Omics Approach 19:03 – DNA and Genomics 22:17 – Transcriptomics and RNA 24:24 – Proteomics and Inflammation Markers 32:00 – The Human Exposome 34:55 – Key Health Biomarkers 36:58 – Cell Membrane Dynamics 40:28 – Biological Investment Strategy 41:53 – Life Extension Possibilities 48:52 – Bioenergetics and Mitochondria 49:47 – Quantum Medicine and the Future 51:33 – Vagal Nerve Stimulation See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr Eugene Manley grew up in Detroit in the 1980s cycling through emergency rooms 20 to 30 times a year with asthma and anaphylaxis while hospital staff talked past his family and buried them in paperwork they could not decode. He responded by earning a BS in mechanical engineering an MS in biomedical engineering and a PhD in molecular biology cell biology and biochemistry. Along the way he tore his ACL training for a jiu jitsu black belt worked 86 straight days in a lab during his doctorate and learned how academic and clinical systems punish people who refuse to shrink.In this episode Manley walks through a recent post surgery ordeal at Mount Sinai Queens where staff falsified records attempted an illegal discharge and nearly sent him home on the wrong blood thinner. He explains how medical racism shows up in charts staffing and decision making and why measurable equity fails without accountability. Listeners hear how his STEMM and Cancer Health Equity Foundation builds pipelines for underrepresented students challenges clinical trial design and teaches patients how to protect themselves when institutions lie. RELATED LINKS• Eugene Manley Jr• STEMM and Cancer Health Equity Foundation• Village Voice• LUNGevity FoundationFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

#403 In this episode, Guy introduced Dr. Lara Varden, a functional genomics practitioner, but the conversation focused largely on her personal healing journey rather than DNA. Dr. Varden described a severe 2001 rear-end collision that left her disabled, in chronic pain, and taking 21–22 prescription medications, leading to multiple spine surgeries and years of impairment. After reading Dolores Cannon's "The Three Waves of Volunteers and the New Earth," she sought a QHHT session in 2015 and says she stopped using her cane immediately and weaned off 14 years of medications within a month, which reframed her approach to integrating science with metaphysical healing. She returned to academia, completed her studies, pursued a funded PhD focused on spine-related research, and later blended holistic, trauma-informed, and energy-based perspectives with scientific genetics and epigenetics. Near the end, they discussed how DNA testing can guide personalized health strategies—especially detoxification and nutrient pathways—shared examples from Guy's genetics, and direct listeners to The DNA Company website, email, and app for reports, education, and testing options. About Dr. Lara: Dr. Lara Varden, Ph.D., is a multi-credentialed clinical practitioner and expert in Precision Medicine. With certifications in functional genomics, nutrition, and holistic health, she has made significant contributions to genetic research and education. In 2024, Dr. Varden helped develop The DNA University, creating training materials to improve patient care globally. Her work spans cellular biology, molecular genetics, and neuroscience, with a focus on empowering people through nutrition and lifestyle changes. As Dean of Students, she emphasizes integrity, proven science, and personalized healing in her practice. Key Points Discussed:  (00:00) - A PhD on 22 Medications Found Dolores Cannon — And Everything Changed! (06:14) - Dr. Lara's Background: From Figure Skater to Scientist (11:38) - The Devastating Car Accident (18:10) - Life on 22 Medications (20:11) - Returning to School Despite Disability (25:11) - The QHHT Session That Changed Everything (27:53) - Miraculous Healing: Off All Medications in One Month (33:48) - PhD Journey: Bridging Science and Spirituality (45:19) - Holistic Healing Philosophy: Root Causes Not Symptoms (57:46) - DNA as Your Body's Blueprint How to Contact Dr. Lara Varden, Ph.D.:thednacompany.com   About me:My Instagram: www.instagram.com/guyhlawrence/?hl=en Guy's websites:www.guylawrence.com.au www.liveinflow.co

In this powerful episode, we sit down with Dr. Joe Zundell — aka “Cancer Daddy” — for a wide-ranging conversation on cancer science, early detection, and what's actually moving the field forward. We cover: • Multi-cancer early detection (MCED) testing and the promise of liquid biopsies • Accuracy, limitations, and clinical decision-making • Metabolic vulnerabilities in cancer (Warburg effect, glutamine dependence) • Epigenetics and tumor biology • Immunotherapy, targeted therapies, and radiopharmaceuticals • Translational research and the bench-to-bedside gap • Drug resistance and evolutionary pressure in cancer treatment • Personalized risk reduction and prevention strategies We also get very personal in this episode — discussing loss, integrity in academia, career pivots, and what truly drives Dr. Zundell's mission in cancer research. This is an honest, science-first, and deeply human conversation about cancer, prevention, innovation, and responsibility in modern medicine. Coach Vinny Email: vinny@balancedbodies.io Instagram: vinnyrusso_balancedbodies Facebook: Vinny Russo Dr. Eryn Email: dr.eryn@balancedbodies.io Instagram: dr.eryn_balancedbodies Facebook: Eryn Stansfield Dr. Joe Zundell Email: drjoezundell@gmail.com Instagram: dr.joezundell LEGION 20% OFF CODE Go to https://legionathletics.com/ and use the code RUSSO for 20% off your order!

In this episode of Hema Now, Anna Schuh discusses the evolution of precision medicine in haematology. From her early inspiration to pursue haematology to her pioneering work in chronic lymphocytic leukaemia, she reflects on how whole genome sequencing, single-cell technologies, and circulating tumour DNA are transforming risk prediction and treatment strategies.   Timestamps:   00:00 – Introduction  02:20 – What drew Anna to haematology  03:57 – Chronic lymphocytic leukaemia  08:55 – Genomics reshaping high risk chronic lymphocytic leukaemia  12:19 – OxPLoreD and STELLAR aims  15:52 – Liquid biopsies  19:56 – Global diagnostics implementation challenges  25:57 – Integrating molecular testing clinically  29:20 – Training future precision leaders  33:51 – Next breakthroughs in precision haematology  35:35 – Three magic wishes 

In today's episode, Lindsey is joined by Dr. Sara Szal Gottfried MD, Director of Precision Medicine at the Marcus Institute of Integrative Health at Thomas Jefferson University, and multiple New York Times bestselling author, to journey into the world of psychedelic medicine and autoimmunity. Morning Microdose is a podcast curated by Krista Williams and Lindsey Simcik, the hosts and founders of Almost 30, a global community, brand, and top rated podcast. With curated clips from the Almost 30 podcast, Morning Mircodose will set the tone for your day, so you can feel inspired through thought provoking conversations…all in digestible episodes that are less than 10 minutes. Wake up with Krista and Lindsey, both literally and spiritually, Monday-Friday. If you enjoyed this conversation, listen to the full episode on Spotify here and on Apple here.

Jenny Opalinski has spent more than a decade inside hospitals where people lose the ability to speak, breathe, swallow, and sometimes survive. A medical speech language pathologist by training, she worked in ICU, neuro rehab, and long term acute care settings, including a Level 1 trauma center, where she watched clinicians absorb 10 to 15 traumatic events in a single shift and then get told to move the crash cart faster next time.That lived reality pushed her to co found The Wellness Shift, an advocacy and education platform focused on healthcare worker burnout, suicide, and assault. In this conversation, Opalinski walks through the moment that changed everything for her: standing in a hospital hallway listening to a family wail after a failed code, followed by a debrief that addressed logistics and ignored grief entirely.She also explains how that work led to Humanity Rx, her podcast about the human cost of medicine, and Dragon's Breath: Calming Tricks for Big Feelings, a children's book that translates evidence based breathing and regulation strategies into language kids can actually use. The episode covers moral injury, time scarcity, false wellness, respiratory muscle training, and why empathy keeps getting treated as an optional expense instead of clinical infrastructure.RELATED LINKSJenny Opalinski on LinkedInThe Wellness ShiftHumanity RxDragon's Breath: Calming Tricks for Big FeelingsAspire Respiratory ProductsFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This podcast was created using NotebookLM.This podcast explores the shift from a one-size-fits-all medical model toward precision medicine, a data-driven strategy that tailors healthcare to an individual's unique genetic and environmental profile.

When Eric Lefkofsky's wife was diagnosed with breast cancer, it exposed how little technology and data were shaping cancer care, pushing the serial entrepreneur to build a different model.Lefkofsky is the founder and CEO of Tempus, now a $10B publicy traded health tech company, and previously founded Groupon. At Tempus, he's building a tech-first company applying multimodal data and AI to make diagnostics smarter and treatment decisions more tailored, starting in oncology and expanding across disease areas.We cover:What Tempus does in plain EnglishWhy Tempus built its own lab, and how it became one of the largest sequencers of cancer patients in the U.S.The hard part: extracting usable clinical data from EHRs and scaling to thousands of hospital connections and hundreds of petabytes of dataHow AI changes the patient-physician relationship, and why patients will increasingly arrive highly informedWhat Eric would change at CMS and HHS to responsibly pay for AI—About our guest: Eric Lefkofsky is the founder and CEO at Tempus, a leader in artificial intelligence and precision medicine. He is the co-founder and General Partner of Lightbank, a private venture capital firm specializing in investments in technology companies. He is also the co-founder of Pathos AI, a clinical stage biotechnology company focused on re-engineering drug development; Groupon (NASDAQ: GRPN), a global e-commerce marketplace; Mediaocean, a leading provider of integrated media procurement technology; Echo Global Logistics (NASDAQ: ECHO), a technology-enabled transportation and logistics outsourcing firm; and InnerWorkings (NASDAQ: INWK), a global provider of managed print and promotional solutions.He co-chairs the Lefkofsky Family Foundation with his wife Liz to advance high-impact initiatives that enhance lives in the communities served. Lefkofsky also serves on the board of directors of The Art Institute of Chicago and Northwestern Medicine. He holds a bachelor's degree from the University of Michigan and a J.D. from the University of Michigan Law School.—

In this episode of the GSD Presents Silicon Valley AI & Tech series, we sit down with the visionary founders of Matrix Edge Therapeutics, Elaine Phan and Andreas Taylor.We dive deep into how they are building the "Signal → Cure → Longevity" AI infrastructure to revolutionize drug discovery and patient stratification. Learn how continuous patient signals and agentic AI are being used to reduce clinical trial-and-error, speed up cure development, and ultimately extend human healthspan.Key Topics Covered:The shift from reactive medicine to AI-driven Precision Medicine.How "Continuous Patient Signals" improve subtyping and stratification.The role of AI in streamlining the lifecycle from drug discovery to post-market management.The future of longevity and bio-tech innovation.About the Guests:Elaine Phan: Founder of Matrix Edge Therapeutics, Biopharma leader (20+ years), NIH AI strategist, and UC Berkeley/Stanford/Georgia Tech alumna.Andreas Taylor: Co-Founder & CTO, Genentech veteran, Data Scientist, and expert in agentic AI applications and drug delivery.Connect with GSD Venture Studios: gsdvs.com#PrecisionMedicine #AIinHealthcare #Longevity #DrugDiscovery #Biotech #GSDVS #TopGlobalStartups #HealthTech #BioPharma

In this episode of Healthcare Happy Hour, David Saltzman interviews Lena Chaihorsky, co-founder and senior vice president of Payer Innovation at Alva10, discussing the concept of precision medicine and its implications for healthcare delivery. They explore the importance of pharmacogenomics, the role of brokers in implementing precision medicine, and the need for education among employers regarding these innovative healthcare solutions. Lena emphasizes the significance of drug efficacy and the financial implications of non-optimized medications, while also highlighting real-world applications and future directions for the NABIP's Precision Medicine Task Force.

Sunstone Health CEO Joshua Resnikoff joins Chris Lustrino to explain how Sunstone uses AI on healthcare claims data to proactively identify children with developmental delay—starting with epilepsy and autism—and help families reach the right specialists and diagnostics faster.They break down what claims data is, why the healthcare system is reactive by default, and how Sunstone's approach can compress what often takes years into roughly weeks by flagging high-need cases, coordinating advanced diagnostics, and delivering actionable next steps. Joshua also shares Sunstone's go-to-market strategy (positioned as an employer-paid benefit), why the pricing model is designed to reduce “point-solution bloat,” and how expansion could move across employers, TPAs, reinsurers, and large insurers. 00:00 Needle-in-a-haystack intro03:13 What Sunstone does (AI + claims data)05:32 Flagging patients vs. diagnosing07:21 Employer benefit + privacy model15:54 GTM + sales cycle reality17:57 Outcome-based pricing model20:16 Unit economics ($10k per case)22:11 Expansion paths + other diseases26:23 Fundraise use of proceeds28:03 Investor closing

The daughter of a hospital administrator, Amy Gleason never considered a career in the public sector – she went straight into healthcare. As an emergency room nurse, she started to see the dangers that unfold when healthcare providers don't have access to the information they need to treat patients. Those experiences drove her towards a tech career in the emerging electronic health records space before a very personal experience altered her professional path yet again.Amy's active and healthy 10-year old daughter began suffering unusual healthcare events, from rashes and headaches to broken bones. Eventually, she couldn't walk. It took more than a year from the start of these symptoms for doctors to diagnose her with a rare autoimmune disease. Even then, it was an accidental diagnosis from a dermatologist conducting a skin biopsy.Amy attributes the delayed diagnosis to siloed data, not unsimilar to the challenges she experienced as a nurse and was working to solve in the EHR space. It motivated her to co-found a company focused on helping patients with chronic diseases access their data to share it with the providers and family members helping to navigate complex care journeys.In 2015, Amy's work earned her an award from the White House for Champions of Change in Precision Medicine – her first foray into the public sector. By 2018, she entered civic service full time with a role at the United States Digital Service, which she describes as “DOGE 1.0.”In this episode of Healthcare is Hard, Amy talked to Keith Figlioli about the work she's doing now as Strategic Advisor to CMS and Administrator of the U.S. DOGE Service, where her main mission is modernizing technology across government agencies for the millions of people who rely on federal services every day. This ranges from modernizing FAFSA and the student loan process, to improving the Visa system ahead of the World Cup, and work on various critical healthcare systems. Some of the topics Amy and Keith discussed in this episode, include:Bold plans for a Digital Health Ecosystem. Launched in July 2025, CMS' Health Tech Ecosystem is a public-private partnership designed as a voluntary, fast-moving alternative to slow rulemaking. Rather than years of regulation, the program uses pledges, working groups, and short development cycles to put interoperability building blocks and real patient-facing use cases in place. The goal is to get usable capabilities into the market in months – not years – let the community iterate, and have baseline use cases live by March 31, 2026 with more advanced capabilities rolling out by July.Carrots and sticks before regulation. Recognizing the limitations of regulation, Amy talked about a new philosophy for incentivizing the market to change behaviors on its own first. “Carrots” include the rural health transformation fund and the recently introduced ACCESS model, a 10-year pilot that, for the first time, lets tech-enabled services bill Medicare directly. “Sticks” include stricter enforcement of information-blocking rules.Replacing the 1970s-era Medicare claims system. Amy discussed plans to replace Medicare's decades-old COBOL-based adjudication platform. While it's a stable platform, it can't support real-time processing, AI, or rapid change. To replace it, CMS is looking to commercial, off-the-shelf solutions that operate at scale so claims processing can be modernized, made real-time, and integrated with new interoperability rails. It's a concrete example of bringing modern engineering and product thinking to government technology.To hear Amy and Keith discuss these topics and more, listen to this episode of Healthcare is Hard: A Podcast for Insiders.

Dr. Jennifer Perusini, CEO and Founder of Neurovation Labs, is developing a precision medicine platform to create targeted therapeutics and diagnostic tools that treat specific brain regions to address central nervous system diseases. For the treatment of PTSD, the approach focuses on the overactive amygdala due to dysregulated glutamate signaling. This objective, brain-based approach of treating a discrete part of the brain rather than the whole brain moves mental health treatment beyond the current one-size-fits-all approach, reducing side effects and improving outcomes. Jennifer explains, "What we are doing is really taking an objective, precision approach to treating mental health disorders, something like an oncology model. So what we really care about is that mental health disorders and psychiatric disorders are rooted in brain dysfunction, yes, but critically that dysfunction occurs in very discreet brain regions and circuits, not necessarily uniformly across the entire brain. So we have really developed a platform designed to identify compounds with dual potential. Precision therapeutics that act on specific brain regions, as well as diagnostic imaging agents that can reveal receptor-level dysfunction and circuit activity in the brain. And so our lead asset and main indication right now is for PTSD, post-traumatic stress disorder." "I think that academics like to focus on this research in very specific brain regions, but that therapeutic angle really hasn't caught up yet. And so, really more specifically, what we're doing is focusing on a very particular signal, an excitatory neurotransmitter in the brain called glutamate, which is a key regulator of neural activity and cell firing. And so there are many disorders, including PTSD, that are affected by dysregulated glutamate signaling. However, the glutamate drugs that are on the market today really bind to the whole brain. So that's just something that hasn't caught up yet, and that's what we're trying to do." #NeurovationLabs #PrecisionMedicine #PTSD #Neuroscience #MentalHealthInnovation #Biomarkers #DrugDiscovery #Glutamate #BrainHealth #DigitalHealth #HealthTech NeurovationLabs.com Download the transcript here

Dr. Jennifer Perusini, CEO and Founder of Neurovation Labs, is developing a precision medicine platform to create targeted therapeutics and diagnostic tools that treat specific brain regions to address central nervous system diseases. For the treatment of PTSD, the approach focuses on the overactive amygdala due to dysregulated glutamate signaling. This objective, brain-based approach of treating a discrete part of the brain rather than the whole brain moves mental health treatment beyond the current one-size-fits-all approach, reducing side effects and improving outcomes. Jennifer explains, "What we are doing is really taking an objective, precision approach to treating mental health disorders, something like an oncology model. So what we really care about is that mental health disorders and psychiatric disorders are rooted in brain dysfunction, yes, but critically that dysfunction occurs in very discreet brain regions and circuits, not necessarily uniformly across the entire brain. So we have really developed a platform designed to identify compounds with dual potential. Precision therapeutics that act on specific brain regions, as well as diagnostic imaging agents that can reveal receptor-level dysfunction and circuit activity in the brain. And so our lead asset and main indication right now is for PTSD, post-traumatic stress disorder." "I think that academics like to focus on this research in very specific brain regions, but that therapeutic angle really hasn't caught up yet. And so, really more specifically, what we're doing is focusing on a very particular signal, an excitatory neurotransmitter in the brain called glutamate, which is a key regulator of neural activity and cell firing. And so there are many disorders, including PTSD, that are affected by dysregulated glutamate signaling. However, the glutamate drugs that are on the market today really bind to the whole brain. So that's just something that hasn't caught up yet, and that's what we're trying to do." #NeurovationLabs #PrecisionMedicine #PTSD #Neuroscience #MentalHealthInnovation #Biomarkers #DrugDiscovery #Glutamate #BrainHealth #DigitalHealth #HealthTech NeurovationLabs.com Listen to the podcast here

This podcast was created using NotebookLM.This podcast discusses how modern dentistry often relies on a standardized scheduling model that prioritizes production goals over the specific biological and emotional requirements of the individual. 

The data necessary to achieve the promise of precision medicine are now available with low-cost whole-genome sequencing, microbiome analysis, proteomics, and other large datasets. Bioscope has developed a team of AI personas to help clinicians realize that promise in a way that will revolutionize the practice of medicine.In this episode, Sandy Vance speaks with Don Brown, MD, Founder and CEO of Bioscope, about how AI and large-scale biological data are converging to make precision medicine practical for clinicians. They explore Don's entrepreneurial journey, the origins of Bioscope, and how a subscription-based, clinician-first approach is shaping the future of personalized care.In this episode, they talk about:Don Brown's unconventional journey from double-wide to CEO of a groundbreaking companyThe inspiration behind founding Bioscope and the problem it was created to solveHow Don's “entrepreneurial bat signal” attracted talent, partners, and early momentumWhy Bioscope began by partnering with concierge medical practices rather than large health systemsHow Bioscope's per-patient, per-year subscription model works in practiceReal-world use cases and early case studies demonstrating clinical impactWhat the current early rollout looks like and where Bioscope is headed nextA Little About Don:Don Brown, MD, is a serial software entrepreneur, physician, and leader in precision medicine. Over his career, he has founded and scaled multiple groundbreaking technology companies, including Software Artistry, Interactive Intelligence, LifeOmic, and most recently Bioscope.AI. His companies have collectively generated billions in value through public offerings and acquisitions by organizations such as IBM, Genesys, and Fountain Life. In addition to his entrepreneurial work, Don is an active advisor, investor, and philanthropist, including a $30 million gift that established the Brown Immunotherapy Center at Indiana University School of Medicine.Don holds a bachelor's degree in physics and a master's degree in computer science from Indiana University, an MD from Indiana University School of Medicine, and a master's degree in biotechnology from Johns Hopkins University. A lifelong learner, he is fluent in multiple languages, an instrument-rated pilot, an avid outdoorsman, and the author of Understanding Life. He currently serves as Founder and CEO of Bioscope.AI, where he is focused on transforming how clinicians use data to deliver personalized care.

In this episode of IDEA Collider, host Mike Rea sits down with Michelle Werner, CEO of Alltrna, to explore a groundbreaking approach that could transform how we treat thousands of genetic diseases. Michelle shares how engineered transfer RNA (tRNA) technology has the potential to address nonsense mutations — a single class of genetic errors that account for roughly 10% of genetic diseases, affecting millions worldwide. Rather than the traditional “one drug, one disease” model, Alltrna is pursuing a mutation-targeted strategy that could treat multiple diseases with a single therapeutic platform. Episode Timestamps;00:00 Welcome to Idea Collider: Asymmetric Learning in Pharma00:19 Meet Michelle Werner: Leading Alltrna's tRNA Platform02:09 From Cancer Clinic to Pharma: A Patient-First Career Path06:18 Big Pharma vs Biotech CEO: Finding Your Authentic Leadership Style09:37 Vulnerability & Psychological Safety: Building High-Trust Teams11:46 A Personal Turning Point: Her Son's Duchenne Diagnosis17:11 Rare Disease Renegades: A Nonprofit to Accelerate Innovation18:19 Why Flagship Pioneering: The Ecosystem Behind Alltrna22:31 tRNA 101: Targeting Stop-Codon Disease Across Thousands of Conditions28:46 Rethinking Trials, Indications & FDA Pathways for Mutation-First Medicines33:49 From Preclinical to First-in-Human: Alltrna's 2026 Milestones36:49 What Keeps a CEO Up at Night + Final Takeaway: Is This Rare Disease's Inflection Point? Michelle also reflects on how her personal experience as a parent of a child with a rare condition fuels her commitment to accelerating therapies for patients who currently have few or no options. This episode highlights a pivotal question for the industry:Are rare diseases at the same inflection point oncology experienced two decades ago? Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Michelle Werner;LinkedIn: https://www.linkedin.com/in/michelle-c-werner/Website: https://www.alltrna.com/ Follow Mike Rea On;Website: https://www.ideapharma.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

Sarah Gromko and Matthew Zachary go back to SUNY Binghamton in the early 1990s, when they were barely 19 and living inside rehearsal rooms. She starred in campus musical theater productions. He served as pianist and music director for many of those shows and played rehearsal piano for the THEA101 repertory company. This episode reunites two former theater nerds who grew up and took very different paths through art, illness, and work that still circles the same truth.Gromko trained as a singer and composer, studied film scoring at Berklee College of Music, worked in New York and New Orleans, then moved into healthcare as a speech language pathologist and recognized vocologist. She explains aphasia, apraxia, dysarthria, and dysphagia with clarity earned from the clinic. She recounts helping a 16 year old gunshot survivor in New Orleans speak again using Melodic Intonation Therapy. The conversation covers voice banking for ALS, gender affirming voice care, and the damage caused when medicine confuses speech loss with intelligence loss. The result feels like an epic reunion powered by 1990s nostalgia and sharpened by decades of lived consequence.RELATED LINKSSarah GromkoGramco VoiceMelodic Intonation TherapyFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Youngberg introduces a precision medicine approach to Alzheimer's and explains why identifying multiple personal risk factors brings hope for true reversal. #AlzheimersPrevention #PrecisionMedicine #BrainHealth #HealthTalks

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore a series of significant shifts in the industry, marked by leadership changes, scientific advancements, strategic partnerships, and regulatory challenges.Starting with Sanofi, a notable leadership transition has taken place as Paul Hudson steps down from his role as CEO. Belen Garijo from Merck KGaA has stepped into this pivotal role. Her appointment is part of a broader industry trend toward diversifying leadership, especially with more women leading top-tier pharmaceutical companies. The implications of this shift could be profound for Sanofi, potentially stabilizing its operations and revitalizing its research pipeline. Stakeholders are keenly observing how this new leadership might steer Sanofi through complex market dynamics.In regulatory news, Moderna has encountered a significant hurdle with the FDA declining to review its next-generation mRNA flu vaccine. This decision has sparked an ongoing public dialogue between Moderna and U.S. health regulators, underscoring the complexities involved in navigating regulatory pathways for novel mRNA technologies beyond their initial success with COVID-19 vaccines. The Department of Health and Human Services has supported the FDA's decision, emphasizing the critical importance of meticulous scrutiny when it comes to new vaccine platforms. This development highlights the challenges biotech companies face in ensuring compliance with stringent regulatory standards.Financial updates reveal CSL experiencing a sharp decline in net profits, dropping from $2 billion to $384 million year-over-year. This financial downturn has been linked to strategic missteps or operational inefficiencies within the company, prompting a change in leadership. Such shifts reflect broader challenges faced by companies within the biotech sector as they strive to maintain financial stability amid fluctuating market conditions.In contrast, Alnylam Pharmaceuticals has reported its first profitable year despite underwhelming sales figures for its drug Amvuttra in the ATTR-CM market. This milestone is significant for Alnylam as it demonstrates resilience and the potential to pivot successfully amidst market uncertainties. However, the company will need to remain vigilant about revenue streams and market dynamics moving forward.Turning to advertising strategies, Johnson & Johnson's Tremfya continues to buck industry trends by maintaining a strong presence in television advertising through 2026. This strategy is noteworthy given the general decline in traditional media spending across the industry. J&J's commitment highlights its determination to sustain market share against competitors such as AbbVie's Rinvoq and Skyrizi.On the strategic front, Takeda Pharmaceuticals is consolidating its U.S. operations by reducing its Boston presence. By subleasing over 630,000 square feet of office space, Takeda aims to streamline operations and concentrate resources on key development projects at its new Cambridge hub. This move reflects broader industry trends towards operational efficiency and resource optimization.In clinical advancements, BridgeBio has reached a promising milestone with successful Phase 3 trial results for infigratinib in treating dwarfism. This breakthrough offers new therapeutic options for children affected by this condition and exemplifies ongoing innovations in genetic medicine. The success of this trial positions BridgeBio on a path toward regulatory approval, potentially transforming care for patients with limited treatment options.Agilent has achieved FDA approval for its companion diagnostic test alongside Merck's Keytruda for ovarian cancer treatment. This approval highlights the growing importance of precision medicine in oncology, where tailored treatments based on individual paSupport the show

In this episode of Disruption/Interruption, KJ sits down with Julian Circo, Co-Founder of Hyfe, a company revolutionizing respiratory health diagnostics through AI-powered cough monitoring. Julian shares his unconventional journey from humanitarian work in post-conflict zones to building the world's largest cough dataset—over 700 million samples. The conversation explores how Hyfe is transforming coughing from a subjective symptom into an objective, quantifiable biomarker, enabling better research, drug development, and patient care. Julian discusses the challenges of disrupting the conservative pharmaceutical industry, the surprising complexity of measuring coughs, and Hyfe's groundbreaking digital therapeutic for chronic cough sufferers. Four Key Takeaways [0:41] Coughing is Medicine's Most Common Yet Least Understood Symptom - Despite being the single most common symptom in medicine for over a century, medical science still cannot answer basic questions like "what is a normal amount of coughing for a healthy person?" Even top pulmonologists disagree significantly on this fundamental question. [11:27] Building the World's Largest Cough Dataset Required Creative Problem-Solving - Hyfe collected over 700 million cough samples by launching a free consumer app during COVID-19 that monitored coughs in the background. This approach solved the critical challenge of gathering diverse, real-world data across different demographics, environments, and microphones—essential for training accurate AI models. [21:52] Pharma's Resistance to Disruption is Actually Rational - The pharmaceutical industry's notorious resistance to innovation stems from legitimate needs: trials spanning months or years require consistent measurement methods to compare data over time. Hyfe succeeded by "leading with science" rather than pitching disruption, focusing on the measurable value they create. [27:30] A Digital Therapeutic Offers Hope Where 15 Drug Trials Failed - Over the past 13 years, 15 pharmaceutical molecules for chronic cough treatment have failed clinical trials. Hyfe is developing a digital therapeutic based on behavioral cough suppression therapy—similar to physical therapy for joints—that has already shown 40% efficacy in preliminary research, offering hope to the one in ten Americans suffering from chronic cough. Quote of the Show (4:28):"People innovate as a way of life. It’s not a luxury. You have to find ways to communicate. You have to find ways to access goods. You have to find ways to make do…” – Julian Circo Join our Anti-PR newsletter where we’re keeping a watchful and clever eye on PR trends, PR fails, and interesting news in tech so you don't have to. You're welcome. Want PR that actually matters? Get 30 minutes of expert advice in a fast-paced, zero-nonsense session from Karla Jo Helms, a veteran Crisis PR and Anti-PR Strategist who knows how to tell your story in the best possible light and get the exposure you need to disrupt your industry. Click here to book your call: https://info.jotopr.com/free-anti-pr-eval Ways to connect with Julian Circo: LinkedIn: https://www.linkedin.com/in/icirco/Company Website: https://www.hyfe.com/Failed Chronic Cough Candidates: https://support.hyfe.com/hubfs/HTML/failed_antitussives_timeline.htmlCoughPro: https://coughpro.com/ How to get more Disruption/Interruption: Amazon Music - https://music.amazon.com/podcasts/eccda84d-4d5b-4c52-ba54-7fd8af3cbe87/disruption-interruption Apple Podcast - https://podcasts.apple.com/us/podcast/disruption-interruption/id1581985755 Spotify - https://open.spotify.com/show/6yGSwcSp8J354awJkCmJlDSee omnystudio.com/listener for privacy information.

Balancing caregiving and career, Elizabeth Jalazo, M.D. traces how her daughter Evelyn's early feeding challenges and later diagnosis of Angelman syndrome reshape her priorities and professional path. Jalazo describes barriers many families face in rare-disease diagnosis, including a “wait and see” approach, specialist access, and insurance denials, and she emphasizes the value of answers for community, care planning, and research access. At UNC Chapel Hill, Jalazo works as a pediatric geneticist and clinical trialist studying interventional therapies for neurodevelopmental and lysosomal storage disorders, and she serves as chief medical officer of the Angelman Syndrome Foundation. She also leads work on Early Check, an opt-in newborn sequencing program in North Carolina, and shares practical lessons about protecting sleep, building support, and saying no while holding space for hope and joy Series: "Autism Tree Project Annual Neuroscience Conference" [Health and Medicine] [Show ID: 41173]

Balancing caregiving and career, Elizabeth Jalazo, M.D. traces how her daughter Evelyn's early feeding challenges and later diagnosis of Angelman syndrome reshape her priorities and professional path. Jalazo describes barriers many families face in rare-disease diagnosis, including a “wait and see” approach, specialist access, and insurance denials, and she emphasizes the value of answers for community, care planning, and research access. At UNC Chapel Hill, Jalazo works as a pediatric geneticist and clinical trialist studying interventional therapies for neurodevelopmental and lysosomal storage disorders, and she serves as chief medical officer of the Angelman Syndrome Foundation. She also leads work on Early Check, an opt-in newborn sequencing program in North Carolina, and shares practical lessons about protecting sleep, building support, and saying no while holding space for hope and joy Series: "Autism Tree Project Annual Neuroscience Conference" [Health and Medicine] [Show ID: 41173]

Balancing caregiving and career, Elizabeth Jalazo, M.D. traces how her daughter Evelyn's early feeding challenges and later diagnosis of Angelman syndrome reshape her priorities and professional path. Jalazo describes barriers many families face in rare-disease diagnosis, including a “wait and see” approach, specialist access, and insurance denials, and she emphasizes the value of answers for community, care planning, and research access. At UNC Chapel Hill, Jalazo works as a pediatric geneticist and clinical trialist studying interventional therapies for neurodevelopmental and lysosomal storage disorders, and she serves as chief medical officer of the Angelman Syndrome Foundation. She also leads work on Early Check, an opt-in newborn sequencing program in North Carolina, and shares practical lessons about protecting sleep, building support, and saying no while holding space for hope and joy Series: "Autism Tree Project Annual Neuroscience Conference" [Health and Medicine] [Show ID: 41173]

Matt Hampton and Dr Tom Ingegno came into my world the way the best guests always do. They found me first. They pulled me onto their Irreverent Health Podcast, a show that blends medicine, curiosity, and unapologetic nonsense the same way Gen X kids blended Saturday morning cartoons with nuclear-war anxiety. We recorded together, we went off the rails together, and by the end I told them the rule. If you ever come to New York, you sit in my studio. No exceptions.They showed up. They took the hot seat. They told Alexa to shut up. They joked about Postmates. They compared bifocals before I even hit record. From there it turned into a full blown eighties time machine powered by weed policy, AI diagnostics, acupuncture philosophy, art school trauma, cannabis data science, paranormal detours, and the kind of deep cut pop culture references only Gen X survivors can decode.Matt builds AI systems. Tom heals people with needles and a lifetime of East Asian medicine. Together they make healthcare funny without pretending it works. They remind you that curiosity carries weight when the system collapses under its own stupidity.This episode is a reunion of three loudmouths raised on Atari, late night cable, and the hard lesson that you either tell the truth or get flattened by it. Go subscribe to Irreverent Health. These guys earned it.RELATED LINKS• Irreverent Health Podcast• Matt Hampton – Consilium Institute• Envoy Design• Dr. Tom Ingegno – Charm City Integrative Health• The Cupping Book• You Got Sick—Now What?• Matt Hampton on LinkedIn• Dr. Tom Ingegno on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In Part 1 of this conversation, Jamie sits down with nurse practitioner Jaclyn Taylor to pull wellness out of the “buzzword” category and into real life. They talk about why so many people feel stuck—fatigued, anxious, gaining weight, losing motivation—and why the first step isn't a perfect plan…it's being listened to. Jaclyn breaks down what the Your Health Wellness Program offers, how bioidentical hormone replacement therapy works, and why “normal labs” don't always mean you're actually okay. This episode is for anyone who's been powering through, silently struggling, or wondering if feeling better is still possible. www.YourHealth.Org

In this episode, Dr. Greg Jones sits down with Dr. Sharon Hausman-Cohen, Chief Medical Officer of IntelliXX DNA, to explore how medical genomics is transforming the way we understand heart disease, brain health, inflammation, and metabolism. Most people think genetics stops at traits like eye color or ancestry. Genomics goes much deeper—analyzing how thousands of genes interact to influence cardiovascular risk, cognitive function, clotting tendencies, nutrient metabolism, and chronic inflammation.Dr. Hausman-Cohen explains why many direct-to-consumer DNA tests fall short, how incomplete interpretation can mislead patients, and why clinician-guided genomic analysis allows for truly personalized care. The conversation also dives into inflammation, methylation, homocysteine, cholesterol myths, caffeine metabolism, mitochondrial health, and women's unique clotting risks.Whether you're trying to reduce your risk of heart disease, improve mental clarity, or understand how your biology responds to diet, supplements, and medications—this episode offers a science-based roadmap for precision health.

This podcast was created using NotebookLM.This podcast discusses how precision medicine uses genomics, AI, and salivary biomarkers to provide personalized dental care for older adults with multimorbidity. 

Today, I have the privilege of connecting with Dr. Sara Gottfried! Dr. Sara is a board-certified physician who graduated from Harvard and MIT. She practices evidence-based, integrative, precision, and functional medicine. She is a Clinical Assistant Professor in the Department of Integrative Medicine and Nutritional Sciences at Thomas Jefferson University and Director of Precision Medicine at the Marcus Institute of Integrative Health. She has written four New York Times bestselling books, including her latest, Women, Food and Hormones.  Dr. Sara is one of my favorite doctors in integrative medicine and GYN! In this episode, we dive into the infodemic, how stress impacts hormones, the impact of age-related changes on hormonal regulation, alcohol, and gender differences with ketogenic lifestyles. We discuss some lesser-known hormones, including growth hormone, and how to support them properly. We touch on disordered eating, how trauma influences our relationship with food, epigenetics, and the role of a lifetime relationship with food. We also look at methylation, glutathione, detox reactions, supporting physical detoxification, and our toxic diet culture. I hope you benefit as much from this episode as I did!  IN THIS EPISODE YOU WILL LEARN: Dr. Sara explains what an infodemic is and how it has affected how she communicates with her patients.  What happens to our hormones as we age? The impact of stress on hormone regulation. Dr. Sara busts the myth that testosterone is a male hormone and discusses what testosterone means for women. How does alcohol consumption impact women's hormones? Why do men tend to have an easier time with the ketogenic diet than women? The dramatic changes that occur in women's bodies as they transition from perimenopause to menopause. Looking at the interrelationship between trauma, stress, and autoimmunity. The changes that occur with growth hormones as we age. How trauma affects the genes. How disordered eating impacts metabolism. How to support physical detoxification naturally, without going to extremes. How to address weight-loss plateaus. Connect with Cynthia Thurlow Follow on X, Instagram & LinkedIn Check out Cynthia's website Submit your questions to support@cynthiathurlow.com Join other like-minded women in a supportive, nurturing community (The Midlife Pause/Cynthia Thurlow)  Cynthia's Menopause Gut Book is on presale now! Cynthia's Intermittent Fasting Transformation Book The Midlife Pause supplement line Connect with Dr. Sara Gottfried On her ⁠website⁠ ⁠Facebook⁠, ⁠Instagram⁠ Dr. Sara's books are available on https://www.saragottfriedmd.com/ and ⁠Amazon.⁠

Why do so many people feel unwell even when their labs are labeled "normal"? Are we using laboratory testing as a guide, or are we letting numbers drive decisions without enough context? In this episode, I sit down with Dr. Ralph Esposito, a board-certified nutritionist, functional medicine practitioner, and expert in metabolic health, to unpack one of the most misunderstood tools in modern medicine: laboratory testing. As Dr. Esposito explains, labs are a cornerstone of healthcare, but they are also among the most frequently misused. We explore how nutrition and metabolic labs should be evaluated responsibly by prioritizing clinical context, pre-test probability, biological variability, and individual response rather than relying on isolated or outdated reference ranges. Our conversation also dives into common misunderstandings around testosterone replacement therapy, cardiovascular risk, and why population-based "normal" values often miss what is happening in the individual. Dr. Esposito introduces an N of 1 framework, reframing labs not as definitive answers but as decision-support tools meant to guide truly personalized care. If you want a clearer, more thoughtful way to interpret labs and assess real health risk, this episode will change how you look at your numbers.   Key takeaways: Lab Interpretation Caution: Misinterpretation of lab results can lead to incorrect health assessments; patient history and context are crucial in lab result analysis. Individualized Guidelines: Dr. Esposito advocates for a shift from population-based to personalized markers of health for more accurate patient care. Role of Testosterone in Health: While TRT can be beneficial, it should be considered carefully, weighing potential health benefits against side effects like elevated hematocrit and hemoglobin levels. Lifestyle Modifications: Recognize the impact of lifestyle changes in conjunction with medical treatments for long-term health improvements. Precision Medicine Vision: The future of healthcare lies in the integration of AI and individualized patient data to tailor precise medical interventions effectively.   More About Dr. Ralph Esposito:   Dr. Ralph Esposito is a licensed naturopathic physician and acupuncturist specializing in precision preventive and integrative medicine. He serves as Chief Science Officer at AG1 where he oversees scientific strategy and clinical research and is an adjunct professor at New York University. His work focuses on evidence-based N-of-1 approaches to risk reduction metabolic health and longevity translating complex science into clinically meaningful outcomes.   Website Instagram Connect with me! Website Instagram Facebook YouTube

Bill Thach has had 9 lines of treatment, over 1,000 doses of chemo, and more scans than an airport. He runs ultramarathons for fun. He jokes about being his own Porta Potty. He became a father, then got cancer while his daughter was 5 months old. Today she is 8. He hides the worst of it so she can believe he stands strong, even when he knows that hiding has a cost.We talk about the illusion of strength, what it means to look fine when your body is falling apart, and how a random postcard in an MD Anderson waiting room led him to Man Up to Cancer, where he now leads Diversity and AYA Engagement. Fatherhood. Rage. Sex. Denial. Humor. Survival. All that and why the words good morning can act like a lifeline.RELATED LINKSFight Colorectal CancerCURE TodayINCA AllianceMan Up to CancerWeeViewsYouTubeLinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The most effective way to drive change in healthcare is to focus on what remains constant: serving patients. In this episode, sponsored by Amgen. Leandro Boer, Vice President of US Medical and General Medicines at Amgen, discusses how the company is reimagining care delivery to enhance access and outcomes, particularly for underserved populations. He explains how precision medicine, multi-omics, and advanced data use are driving innovation and preventing “data waste,” while Amgen invests heavily in R&D, including a $600 million Innovation and Discovery Science Center. Leandro highlights the role of technology in accelerating clinical trials through machine learning and anticipates three major shifts within the next five years: faster drug development, reduced administrative burden through the use of AI, and improved patient identification via care pathway automation. He also highlights Amgen's goal to reduce cardiovascular events by 50% by 2030, the importance of diverse clinical representation through the RISE initiative, and the company's commitment to employee well-being as the foundation for improved patient care. Tune in and learn how innovation, equity, and purpose-driven leadership are transforming the future of healthcare! Resources: Connect with and follow Leandro Boer on LinkedIn. Follow Amgen on LinkedIn and explore their website.

Is modern medicine still evidence-based, or have we quietly mistaken rigor for certainty?Evidence-based medicine is essential. It's why we save lives, advance care, and trust modern healthcare. But as medicine has become more specialized and disease more complex, something subtle has happened. Rigor has increasingly turned into reductionism, and evidence is often applied in ways that don't fully match the realities of clinical practice or patients' lived experiences.In this episode of The Trip Lab, I take a careful look at what we mean when we say “evidence-based medicine.” We explore the difference between statistical significance and clinical significance, how guidelines are created and why they are evidence-informed rather than infallible, and why many patients feel unwell despite having “normal” labs.This conversation also examines how modern research methods struggle to capture complexity, particularly in chronic, system-level disease. We look at where reductionism has helped medicine advance, where it now falls short, and why ancient healing systems and emerging fields like systems biology, functional medicine, and precision medicine are pointing us toward a more integrated future.This episode is not a rejection of evidence. It's an invitation to reclaim it. To restore clinical wisdom alongside data, and to practice medicine with both rigor and curiosity.In this episode, we cover:What “evidence-based medicine” actually means and how it's evolvedStatistical significance vs. clinical significanceThe strengths and limitations of medical guidelinesWhy reductionist models don't fully explain chronic diseaseWhy patients can feel unwell even when labs are “normal”How medicine might evolve to better study complexityWhy medicine is both a science and an artThe podcast name, The Trip Lab, nods to psychedelics, but a “trip,” psychedelic or otherwise, is ultimately an exploration. A willingness to step outside familiar frameworks, question what we think we know, and notice connections that weren't obvious before.If you've ever felt tension between what the data says, what the guidelines allow, and what the patient in front of you actually needs... or if you are a patient who has been failed by modern medicine, this episode is for you.

Is the era of cisplatin over, or are we simply becoming more precise about who benefits from it? As perioperative strategies in bladder cancer continue to evolve, emerging tools like circulating tumor DNA (ctDNA) are playing a bigger role in how clinicians assess recurrence risk and tailor treatment. In this episode of BackTable Tumor Board, host Alan Tan, medical oncologist at Vanderbilt-Ingram Cancer Center, is joined by bladder cancer experts Dr. Amanda Nizam and Dr. Brad McGregor to discuss recent advances in the diagnosis and treatment of urothelial carcinoma. --- SYNPOSIS The doctors examine the evolving management of muscle-invasive bladder cancer (MIBC), including the role of neoadjuvant and adjuvant therapies, the integration of immunotherapy, and the recent approval of enfortumab vedotin plus pembrolizumab. The discussion explores the rapidly changing perioperative landscape, the prognostic utility of ctDNA, and how biomarkers such as HER2 and FGFR are influencing treatment selection across disease states. They also address bladder preservation strategies, management of treatment-related toxicities, and the importance of multidisciplinary coordination. The episode concludes with a forward-looking discussion on emerging therapies and the potential to improve cure rates in bladder cancer. --- TIMESTAMPS 00:00 - Introduction01:44 - Overview of Bladder Cancer Treatment04:54 - Patient Staging and Treatment Goals10:12 - Bladder Preservation vs. Radical Cystectomy16:39 - Emerging Trials and Future Directions22:40 - ctDNA and Precision Medicine33:50 - Metastatic Disease and Biomarker Strategies42:16 - Managing Neuropathy in Metastatic Treatment48:44 - HER2 and FGFR in Bladder Cancer54:15 - Future Directions in Bladder Cancer Treatment --- RESOURCES EV-302/303 Trialhttps://newsroom.astellas.com/2023-12-15-PADCEV-R-enfortumab-vedotin-ejfv-with-KEYTRUDA-R-pembrolizumab-Approved-by-FDA-as-the-First-and-Only-ADC-Plus-PD-1-to-Treat-Advanced-Bladder-Cancer NIAGARA Regimenhttps://www.nejm.org/doi/full/10.1056/NEJMoa2408154 KEYNOTE-905 Studyhttps://www.annalsofoncology.org/article/S0923-7534(25)04894-X/fulltext

Shannon Burkett has lived about six lives. Broadway actor. SNL alum. Nurse. Filmmaker. Advocate. Cancer survivor. And the kind of person who makes you question what you've done with your day. She wrote and produced My Vagina—the stop-motion musical kind, not the cry-for-help kind—and built a global movement after her son was poisoned by lead dust in their New York apartment. Out of that came LEAD: How This Story Ends Is Up to Us, a documentary born from rage, science, and maternal defiance. We talked about everything from The Goonies to Patrick Stewart to the quiet rage of parenting in a country that treats public health like a hobby. This episode is about art, anger, resilience, and what happens when an unstoppable theater nerd turned science geek Jersey girl collides with an immovable healthcare system.RELATED LINKSShannon Burkett Official SiteLEAD: How This Story Ends Is Up to UsEnd Lead PoisoningLinkedIn: Shannon BurkettBroadwayWorld ProfileFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

About Leandro Boer:Leandro Boer, MD, PhD, is a seasoned global biopharmaceutical executive and physician specializing in cardiology and cardiovascular pharmacology. Currently serving as Vice President of US Medical, General Medicines at Amgen, he leads medical strategy and execution across cardiovascular, bone, neuroscience, nephrology, and obesity therapeutic areas, overseeing a nationwide organization of over 100 professionals. With more than two decades of experience spanning the United States, Latin America, Canada, Africa, and the Middle East, Dr. Boer has built a distinguished career at leading companies such as Amgen, AstraZeneca, and Novartis.His leadership has shaped global and regional initiatives in medical affairs, clinical development, real-world evidence generation, regulatory strategy, and implementation science. Clinically, his expertise covers resistant hypertension, type 2 diabetes, obesity, heart failure, chronic kidney disease, and hyperlipidemia. Known for combining scientific rigor with strategic vision, Dr. Boer has directed cross-functional teams supporting drug development, commercialization, and lifecycle management across multiple therapeutic areas.A medical doctor trained in cardiology with a Ph.D. in cardiovascular pharmacology from Universidade Estadual de Campinas, Dr. Boer has consistently demonstrated a commitment to advancing evidence-based medicine, patient outcomes, and collaborative leadership within the healthcare ecosystem.Things You'll Learn:The foundation of innovation lies in focusing on what never changes—patients, healthcare providers, and equitable systems of care.Amgen's precision medicine and data-driven strategies prevent “data waste” and ensure every insight contributes to patient outcomes.Machine learning tools like Atomic are accelerating clinical trials by predicting successful sites, leading to faster drug development.The company's bold goal to reduce cardiovascular events by 50% by 2030 relies on partnerships, AI, and implementation science.Representation in clinical research and decentralized trials is crucial to ensuring equitable access and meaningful outcomes for all populations.Resources:Connect with and follow Leandro Boer on LinkedIn.Follow Amgen on LinkedIn and explore their website.

In this episode of the Eye on AI Podcast, Craig Smith sits down with Steve Brown, founder of CureWise, to explore how agentic AI is reshaping healthcare from the patient's perspective. Steve shares the deeply personal story behind CureWise, born out of his own experience with a rare cancer diagnosis that was repeatedly missed by traditional medical pathways. The conversation dives into why modern healthcare struggles with complex, edge-case conditions, how fragmented medical data and time-constrained systems fail patients, and where AI can meaningfully help without replacing clinicians. The discussion goes deep into multi-agent AI systems, reliability through consensus, large context windows, and how AI can surface better questions rather than premature answers. Steve explains why patient education is the real unlock for better outcomes, how precision medicine depends on individualized data and genetics, and why empowering patients leads to stronger collaboration with doctors. This episode offers a grounded, practical look at AI's role in healthcare, not as a diagnostic shortcut, but as a tool for clarity, context, and better decision-making in some of the most critical moments of car   Stay Updated: Craig Smith on X: https://x.com/craigssEye on A.I. on X: https://x.com/EyeOn_AI (00:00) Using Multi-Agent AI to Analyze Medical Records (04:35) Steve Brown's Tech Background and Return to Healthcare (08:25) How a Rare Cancer Diagnosis Was Initially Missed (13:55) Why Modern Medicine Struggles With Complex Cases (18:29) Multi-Agent Consensus and AI Reliability in Healthcare (24:12) Large Context Windows, RAG, and Medical Data Organization (28:24) Why CureWise Focuses on Patient Education, Not Diagnosis (33:10) Precision Medicine, Genetics, and Personalized Treatment (47:45) Why CureWise Launches Direct-to-Patient First (53:19) The Future of AI-Driven Precision Medicine

Precision Medicine with guest William Oh January 25, 2026 Yale Cancer Center visit: https://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're exploring a series of remarkable advancements and strategic collaborations in the industry, showcasing a dynamic period of innovation and regulatory evolution.Corcept Therapeutics has celebrated a significant win with their Phase 3 trial for relacorilant targeting ovarian cancer, revealing improved overall survival rates. This marks a potential rebound for Corcept following a previous FDA rejection for Cushing's syndrome, setting the stage for an impactful new cancer therapy. The success of this trial underscores the critical importance of positive clinical outcomes in securing regulatory approvals and preparing for market entry.Bristol Myers Squibb has embarked on an ambitious $850 million partnership with Janux Therapeutics to develop a novel tumor-activated therapeutic using T-cell engager technology. This collaboration is part of an ongoing trend towards personalized medicine and immunotherapy, where targeted treatments are preferred for their specificity and reduced systemic toxicity. Such partnerships not only combine resources but also accelerate the development of innovative cancer treatments.Corxel Pharmaceuticals has secured $287 million in Series D funding to advance its oral GLP-1 receptor agonist through Phase 2/3 trials addressing obesity. This significant investment highlights the growing interest in treatments for metabolic disorders, particularly as obesity remains a global health challenge with substantial unmet needs. Oral GLP-1 therapies offer promise given their potential for improved patient compliance compared to injectable forms.The regulatory landscape is also evolving. The FDA has issued draft guidance on utilizing minimal residual disease (MRD) and complete response metrics to support accelerated drug approvals for multiple myeloma treatments. This reflects an adaptive approach aimed at expediting access to life-saving therapies by leveraging advanced biomarkers and response measures. It also signifies a shift towards precision medicine, where treatment efficacy is closely monitored through molecular markers.Hoth Therapeutics has reported promising Phase 2 results addressing skin toxicities caused by EGFR inhibitors, common adverse effects in cancer treatment regimens. Despite this progress in supportive oncology care, Hoth's share price has remained stagnant, potentially due to market skepticism or the need for more data to substantiate clinical benefits.The industry continues to attract significant venture capital, as evidenced by companies like Mendra launching with $82 million to focus on innovative biotech solutions. These financial infusions are crucial for advancing early-stage research into clinical applications.On the legal front, Johnson & Johnson faces challenges with ongoing talc litigation. A court-appointed official has recommended allowing expert testimony on scientific evidence linking talc products to cancer. This could impact J&J's defense strategy and underscores the importance of robust scientific validation in legal contexts.Overall, these developments reflect an industry characterized by robust innovation, strategic collaborations, and evolving regulatory frameworks. The focus on targeted therapies, personalized medicine, and accelerated approval processes underscores a commitment to addressing complex health challenges while enhancing patient care outcomes.Shifting our attention to global trends, Samsung Biologics has achieved a financial milestone by becoming the first Korean biopharmaceutical company to exceed an annual profit of 2 trillion won ($1.4 billion). This accomplishment underscores the company's robust growth trajectory and strategic positioning in the global biopharma landscape, reflecting broader trends where increased demand for biologics and bioSupport the show

What if the missing link in treating autoimmune disease wasn't a new drug—but a better way to measure stress? In this episode of Med Tech Gurus, we sit down with Dr. Andrew Holman, CEO of Inmedix and the innovator behind CloudHRV, the first FDA-cleared platform to measure stress biology with medical-grade precision .At a time when 75% of autoimmune treatments fail—costing billions and leaving patients without answers—CloudHRV delivers actionable insights in just five minutes reframing how clinicians think about chronic disease. Dr. Holman takes us inside his two-decade journey building Inmedix, from early IP strategy to securing partnerships with global pharma. Along the way, he shares lessons on leveraging licensing as a growth strategy, building a culture of innovation, and aligning science, business, and patient care in the pursuit of transformative healthcare solutions. Whether you're a founder, investor, or clinician, this conversation will reshape how you think about precision medicine and the future of patient-centered innovation.

Michael Kramer was 19 when cancer ambushed his life. He went from surfing Florida beaches to chemo, radiation, and a bone marrow transplant that left him alive but carrying a chronic disease. He had necrosis in his knees and elbows, lost his ability to surf for years, and found himself stuck in hospitals instead of the ocean. Yet he adapted. Michael picked up a guitar, built Lego sets, led support groups, and started sharing his story on Instagram and TikTok.We talk about masculinity, identity, and what happens when the thing that defines you gets stripped away. He opens up about dating in Miami, freezing sperm at a children's hospital, awkward Uber-for-sperm moments with his brother, and how meditation became survival. Michael lost his father to cancer when he was a teen, and that grief shaped how he lives and advocates today. He is funny, grounded, and honest about the realities of survivorship in your twenties. This episode shows what resilience looks like when you refuse to walk it off and choose to speak it out loud instead.RELATED LINKSMichael Kramer on InstagramMichael Kramer on TikTokMichael and Mom Inspire on YouTubeAshlee Cramer's BookUniversity of Miami Sylvester Comprehensive Cancer CenterStupid Cancer FEEDBACKLike this episode? Rate and review Walk It Off on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a landscape marked by rapid transformations and strategic maneuvers that are reshaping the industry.Novo Nordisk is at a pivotal point under the leadership of CEO Maziar Mike Doustdar. The company is navigating a significant transition, focusing on reclaiming its leadership in the glucagon-like peptide-1 (GLP-1) market. This is crucial as GLP-1 receptor agonists are central to diabetes and obesity treatments, areas where Novo Nordisk aims to solidify its presence amidst fierce competition.AstraZeneca is setting ambitious targets, aiming for $80 billion in revenue by 2030. Their confidence is buoyed by strong Phase 3 clinical trial performances, particularly in oncology and rare diseases, underscoring the importance of a robust and successful pipeline. AstraZeneca's acquisition of Modella AI marks an integration of advanced AI models into oncology R&D operations, aligning with industry trends leveraging AI for drug discovery processes. By incorporating AI technologies, AstraZeneca aims to revolutionize precision medicine approaches within oncology treatments.Travere Therapeutics finds itself at a critical juncture with the FDA's delayed decision on Filspari (sparsentan) for focal segmental glomerulosclerosis (FSGS). This potential approval could tap into a significant market opportunity, but the delay highlights regulatory challenges that can impact timelines and revenue forecasts.Gilead Sciences continues to strengthen its position in HIV treatment with lenacapavir's approval for bi-annual dosing. This advancement not only enhances patient compliance but also positions Gilead advantageously for strategic partnerships. Their strategic positioning post-approval of lenacapavir for HIV prevention marks a milestone, emphasizing innovation's role in drug formulations.Leo Pharma's pursuit of partnerships in rare dermatological diseases reflects a broader trend towards specialization and diversification into niche markets. Meanwhile, Ionis Pharmaceuticals is gearing up to launch Tryngolza (olezarsen) for new indications, doubling their sales projections and demonstrating confidence in their RNA-targeted therapy.Caldera's emergence with significant funding points to ongoing investor interest in innovative biotech ventures, particularly those involving cross-border collaborations like their licensed drug from China for inflammatory bowel disease. Cross-border collaborations such as Caldera's venture into inflammatory bowel disease treatments are becoming more prevalent, integrating innovations from different regions to accelerate novel therapy availability for complex diseases.Illumina's efforts to navigate export challenges with China highlight geopolitical factors influencing biotech operations and global supply chains. They are actively working to stabilize their business environment while supporting academic research initiatives. Illumina's collaboration efforts with China amidst geopolitical tensions further demonstrate complexities within international trade relations affecting scientific collaborations.The American Medical Association's investment in "precision education" using data analytics exemplifies how technology is reshaping healthcare education and practice, aiming to enhance outcomes by tailoring learning experiences.AbbVie has committed $100 billion to U.S. research and development over the next decade, focusing on biologics and autoimmune disorders. This substantial investment underscores their commitment to innovation while seeking competitive edge enhancements through tariff exemptions.On clinical fronts, significant advancements are being made in therapies targeting rare diseases such as Sentynl Therapeutics' FDA approval for Zycubo—a novel protein therapy addressing Menkes disease—highlightSupport the show

In this episode of Health Matters, host Courtney Allison is joined by Dr. Rekha Kumar, endocrinologist and primary care physician at NewYork-Presbyterian and Weill Cornell Medicine, to unpack the science behind aging well. They discuss biohacking, longevity, and health span, separating evidence-based strategies from social media hype and exploring what truly helps us age well.What You'll Learn in This EpisodeWhat “biohacking” really means● How biohacking ranges from simple lifestyle optimization to high-tech, experimental interventions● The difference between lifespan (how long you live) and health span (how long you live well)The Longevity Pyramid● Why the foundation of healthy aging is built on:SleepMovement and strength trainingNutritionStress managementSocial connection● How advanced tools and supplements sit at the top—and why they should never replace the basicsWearables and Tracking● How devices like smartwatches, glucose monitors, and fitness trackers can support behavior change● When tracking becomes counterproductive or stressfulPeptides and “Anti-Aging” Supplements● What's proven (e.g., metformin, GLP-1 receptor agonists)● What's still experimental or under-studied (BPC-157, sermorelin, NAD boosters)Nootropics and Cognitive Enhancers● Everyday nootropics like caffeine● The role of L-theanine for “calm focus”● Myths around perfectly timed caffeine and cortisol rhythmsNutrigenomics and Personalized Nutrition● How genes can influence responses to foods (e.g., lactose intolerance, APOE and saturated fat)● Why many direct-to-consumer genetic tests may overpromiseThe Gut Microbiome● The role of Akkermansia muciniphila in metabolic health● How medications like metformin and GLP-1s may positively shift gut bacteria● What's still unknown about probiotic supplementationGenetic and Biomarker Testing● The difference between actionable medical insights and “information overload”● Why results of unknown significance can cause unnecessary anxietyThe Big Takeaways● There are no true shortcuts to longevity● Sustainable habits beat quick fixes● Our biology is built for rhythms, not constant optimizationFeatured ExpertAbout Rekha B. Kumar, M.D., M.S.Dr. Rekha B. Kumar is an attending endocrinologist at NewYork-Presbyterian/Weill Cornell Medical Center and an associate professor of Clinical Medicine at Weill Cornell Medicine. She specializes in adult primary care and endocrinology and has academic expertise in the diagnosis and treatment of various endocrine disorders, including obesity/weight management, type 2 diabetes, polycystic ovarian syndrome (PCOS), thyroid disorders, as well as metabolic bone disease.Dr. Kumar completed her undergraduate studies at Duke University and received her masters degree in Physiology from Georgetown University. She received her M.D. from New York Medical College and completed her residency training in Internal Medicine at NewYork-Presbyterian/Weill Cornell Medical Center. Dr. Kumar obtained her clinical fellowship in the combined Diabetes, Endocrinology, and Metabolism program at the NewYork-Presbyterian/Weill Cornell Medical Center and the Memorial Sloan Kettering Cancer Center. Dr. Kumar is Board Certified in Internal Medicine, Endocrinology, Diabetes, & Metabolism, and Obesity Medicine.Coming Up NextIn the next episode of Health Matters, we'll explore brain health and the short- and long-term effects of alcohol on the brain with Dr. Hugh Cahill. Subscribe and follow Health Matters on Apple Podcasts, Spotify, or wherever you listen to stay up to date with expert-driven conversations on living well at every stage of life.About Health MattersHealth Matters is your bi-weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine.To learn more visit: https://healthmatters.nyp.org

Daniel Garza had momentum. Acting roles, directing gigs, national tours lined up. Then anal cancer stopped everything. Radiation wrecked his body, stripped him of control, and left him in diapers, staring down despair. His partner, Christian Ramirez, carried him through the darkest nights, changed his wounds, fought hospitals, and paid the price with his own health. Christian still lives with permanent damage from caregiving, but he stayed anyway.Together they talk with me about masculinity, sex, shame, friendship, and survival. They describe the friendships that vanished, the laughter that kept them alive, and the brutal reality of caregiving no one prepares you for. We get into survivor guilt, PTSD, and why even rocks need rocks. Daniel is now an actor, director, and comedian living with HIV. Christian continues to tell the unfiltered truth about what it takes to be a caregiver and stay whole. This episode gives voice to both sides of the cancer experience, the survivor and the one who stands guard. RELATED LINKSDaniel Garza IMDbDaniel Garza on InstagramDaniel Garza on FacebookChristian Ramirez on LinkedInLilmesican Productions Inc (Daniel & Christian)Stupid Cancer FEEDBACKLike this episode? Rate and review Walk It Off on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of Disruption/Interruption, host KJ sits down with Jurek Kozyra, founder and CEO of Nanovery, to explore how DNA nanotechnology and AI are revolutionizing molecular medicine. Discover how tiny nanorobots made from DNA could dramatically accelerate drug development, make diagnostics faster and more affordable, and potentially cure diseases that were previously untreatable. From detecting diseases in hours instead of days to cutting years off the drug development process, this conversation reveals the cutting-edge science that's transforming healthcare. Four Key Takeaways: The Promise of Oligonucleotide Therapeutics (9:06) Traditional medicine targets defective proteins, but many diseases can't be cured because we can't find the right molecule. Oligonucleotide therapeutics target mRNA—the underlying mechanism of disease—meaning you could potentially cure all diseases since all proteins come from mRNA. DNA Nanorobots for Rapid Detection (14:12) Nanovery's DNA nanorobots can detect diseases in blood samples within 2-4 hours compared to traditional lab tests that take two days. These self-assembling machines produce fluorescent signals when they find specific DNA or RNA molecules, enabling point-of-care diagnostics. Accelerating Drug Development (17:13) Pharmaceutical companies race against 20-year patents while drugs take 10+ years to develop. Nanovery's technology provides more accurate data at lower cost and time, potentially shaving years off the development process and helping more drugs successfully reach the market. Real-World Clinical Validation (20:26) In a hospital study with 170 patient samples, Nanovery's technology delivered same or better results than traditional tests in just two hours instead of two days—a game-changer for emergency situations like drug overdoses where immediate answers are critical. Quote of the Show (9:05):"If you can target mRNA very specifically, that means that in theory you could potentially cure all diseases. That's why this area is so exciting right now." – Jurek Kozyra Join our Anti-PR newsletter where we’re keeping a watchful and clever eye on PR trends, PR fails, and interesting news in tech so you don't have to. You're welcome. Want PR that actually matters? Get 30 minutes of expert advice in a fast-paced, zero-nonsense session from Karla Jo Helms, a veteran Crisis PR and Anti-PR Strategist who knows how to tell your story in the best possible light and get the exposure you need to disrupt your industry. Click here to book your call: https://info.jotopr.com/free-anti-pr-eval Ways to connect with Jurek Kozyra: LinkedIn: https://www.linkedin.com/in/j3ny/ Company Website: https://nanovery.co.uk How to get more Disruption/Interruption: Amazon Music - https://music.amazon.com/podcasts/eccda84d-4d5b-4c52-ba54-7fd8af3cbe87/disruption-interruption Apple Podcast - https://podcasts.apple.com/us/podcast/disruption-interruption/id1581985755 Spotify - https://open.spotify.com/show/6yGSwcSp8J354awJkCmJlDSee omnystudio.com/listener for privacy information.

In this episode of Longevity by Design, host Dr. Gil Blander sits down with Dr. Wei-Wu, Executive Chairman at Human Longevity, Inc. Together, they explore how advances in genome sequencing, AI, and multi-layered diagnostics are changing the fight against age-related diseases. Wei-Wu shares why understanding your own genetic risks and combining them with other health data leads to better prevention and a longer healthspan.Wei-Wu explains the value of integrating genome sequencing, advanced imaging, and liquid biopsy to catch diseases like cancer early, before symptoms appear. He draws on real-world examples, including how combining different tests can spot cancers that single methods might miss. The conversation highlights how technology brings down costs, making once-rare insights widely available, and how each person stands to benefit from personalized risk profiles.The episode closes with practical advice: use today's tools to become the CEO of your own health. Wei-Wu urges listeners to embrace data-driven, individualized care and stresses that no single tool or habit holds all the answers. Instead, true longevity comes from a holistic, ongoing approach, one that uses all available knowledge to prevent disease and extend both life and health.Guest-at-a-Glance

Trevor Maxwell lived the archetype of masculinity in rural Maine. Big, strong, splitting wood, raising kids, and carrying the load. Then cancer ripped that script apart. In 2018 he was bedridden, emasculated, ashamed, and convinced his family would be better off without him. His wife refused to let him disappear. That moment forced Trevor to face his depression, get help, and rebuild himself. Out of that came Man Up To Cancer, now the largest community for men with cancer, a place where men stop pretending they are bulletproof and start being honest with each other.Eric Charsky joins the conversation. A veteran with five cancers, forty-nine surgeries, and the scars to prove it, Eric lays out what happens when the military's invincible mindset collides with mortality. Together, we talk masculinity, vulnerability, sex, shame, and survival. This episode is blunt, raw, and overdue.RELATED LINKSMan Up To CancerTrevor Maxwell on LinkedInDempsey CenterEric Charsky on LinkedInStupid Cancer FEEDBACKLike this episode? Rate and review Walk It Off on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The most anticipated annual tradition on Out of Patients returns with the 2025 Holiday Podcast Spectacular starring Matthew's twins Koby and Hannah. Now 15 and a half and deep into sophomore year, the twins deliver another unfiltered year end recap that longtime listeners wait for every December. What began as a novelty in 2018 has become a time capsule of adolescence, parenting, and how fast childhood burns off.This year's recap covers real moments from 2025 A subway ride home with a bloodied face after running full speed into that tree that grows in Brooklyn. Broadway obsessions fueled by James Madison High School's Roundabout Youth Ensemble access, including Chess, & Juliet, Good Night and Good Luck, and Pirates of Penzance holding court on Broadway. A Disneylanmd trip where the Millennium Falcon triggered a full system reboot. A New York Auto Show pilgrimage capped by a Bugatti sighting. All the things.The twins talk school pressure, AP classes, learner permit anxiety, pop culture fixation, musical theater devotion, and the strange clarity that comes with turning 15. The humor stays sharp, the details stay specific, and the passage of time stays undefeated. This episode lands where the show works best: family, honesty, and letting young people speak for themselves.FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Jason Gilley walked into adulthood with a fastball, a college roster spot, and a head of curls that deserved its own agent. Cancer crashed that party and took him on a tour of chemo chairs, pediatric wards, metal taste, numb legs, PTSD, and the kind of late night panic that rewires a kid before he even knows who he is.I sat with him in the studio and heard a story I know in my bones. He grew up fast. He learned how to stare down mortality at nineteen. He found anchors in baseball, therapy, and the strange friendships cancer hands you when it tears your plans apart. He owns the fear and the humor without slogans or shortcuts. Listeners will meet a young man who refuses to let cancer shrink his world. He fights for the life he wants. He names the truth without apology. He reminds us that survivorship stays messy and sacred at the same time. This conversation will stay with you.RELATED LINKS• Jason Gilley on IG• Athletek Baseball Podcast• EMDR information• Children's Healthcare of AtlantaFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.